A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

February 7, 2023

Study Completion Date

March 7, 2023

Conditions
Sjogren SyndromeMixed Connective Tissue Disease
Interventions
DRUG

MHV370

MHV370 for 24 weeks

DRUG

Placebo

Placebo for 24 weeks

Trial Locations (10)

4032

Novartis Investigative Site, Debrecen

8000

Novartis Investigative Site, Székesfehérvár

10117

Novartis Investigative Site, Berlin

28041

Novartis Investigative Site, Madrid

81346

Novartis Investigative Site, Kaohsiung City

130021

Novartis Investigative Site, Changchun

510000

Novartis Investigative Site, Guangzhou

15 707

Novartis Investigative Site, Bialystok

20-954

Novartis Investigative Site, Lublin

02 637

Novartis Investigative Site, Warsaw

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY